Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy

NCT04278417 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

689

Enrollment

INDUSTRY

Sponsor class

Conditions

Proliferative Diabetic Retinopathy

Interventions

BIOLOGICAL: Brolucizumab 6 mg
PROCEDURE: Panretinal photocoagulation laser

Sponsor

Novartis Pharmaceuticals